Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 27;13:5062. doi: 10.1038/s41467-022-32477-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — a Experimental scheme showing non-diabetic control (C) or diabetic mice without (DM-22) or with intervention to reduce blood glucose levels by sodium/glucose cotransporter-2 inhibitor (Dapagliflozin®, DM + SGLT2i). Mice were age matched and SGLT2i treatment was started after 16 weeks of persistent hyperglycemia (streptozotocin; STZ-induced hyperglycemia). b Average blood glucose levels in the experimental groups after 10, 16 or 22 weeks. c Dot plot summarizing albuminuria (urinary albumin-creatinine ratio, µg albumin/mg creatinine; UACR) in non-diabetic (C) or diabetic mice without (DM-16 and DM-22) or with intervention to reduce blood glucose levels (DM + SGLT2i). d Heat map summarizing gene-expression in experimental groups (C, DM-22, DM + SGLT2i). All genes with significantly changed expression between control and diabetic mice are shown on the left side of the panel and are illustrated by lightly colored boxes in the middle (number of genes shown in black). The subset of genes with persistently changed expression despite reduced blood glucose levels are shown on the right side of the panel and illustrated by the darker colored smaller boxes in the middle (number of genes shown in white). e Volcano plot summarizing the persistently induced and repressed genes in diabetic mice after blood glucose reduction based on Log FC values and FDR. Ckdn1a (p21) belongs to the top persistently induced genes. f Sustained renal p21 mRNA expression (Cdkn1a, qRT-PCR) in vivo (DM-22; T1DM, STZ-model) despite reducing glucose levels (DM + SGLT2i; T1DM, STZ-model) as compared to mice with persistently elevated glucose levels (DM-22) or normoglycemic controls (C). Line graph and dot plots reflecting mean ± SEM of six mice per group; one-way ANOVA with Sidak’s multiple comparison test. Source data are provided as a Source Data file-Fig-1.